Safety, Tolerability and Pharmacokinetic Characteristics of JYP0061 in Healthy Adult Subjects After Single and Multiple Doses: a Single-center, Randomized, Double-blind, Placebo-controlled, Phase I Trial
Latest Information Update: 04 Dec 2023
At a glance
- Drugs JYP-0061 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Guangzhou JOYO Pharma
Most Recent Events
- 23 Nov 2023 New trial record